{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:41:44Z","timestamp":1780504904876,"version":"3.54.1"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00281-019-00756-1","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T14:34:53Z","timestamp":1569335693000},"page":"737-746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Resolution of Crohn\u2019s disease"],"prefix":"10.1007","volume":"41","author":[{"given":"Heike","family":"Schmitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Neufert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus F.","family":"Neurath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Atreya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,24]]},"reference":[{"issue":"3","key":"756_CR1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1172\/JCI30587","volume":"117","author":"W Strober","year":"2007","unstructured":"Strober W, Fuss I, Mannon P (2007) The fundamental basis of inflammatory bowel disease. J Clin Invest 117(3):514\u2013521","journal-title":"J Clin Invest"},{"issue":"8","key":"756_CR2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/ni.3790","volume":"18","author":"MG Netea","year":"2017","unstructured":"Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS, Heneka MT, Hoffman HM, Hotchkiss R, Joosten LAB, Kastner DL, Korte M, Latz E, Libby P, Mandrup-Poulsen T, Mantovani A, Mills KHG, Nowak KL, O'Neill LA, Pickkers P, van der Poll T, Ridker PM, Schalkwijk J, Schwartz DA, Siegmund B, Steer CJ, Tilg H, van der Meer JWM, van de Veerdonk FL, Dinarello CA (2017) A guiding map for inflammation. Nat Immunol 18(8):826\u2013831","journal-title":"Nat Immunol"},{"issue":"27","key":"756_CR3","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.3748\/wjg.14.4280","volume":"14","author":"F Sanchez-Munoz","year":"2008","unstructured":"Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK (2008) Role of cytokines in inflammatory bowel disease. World J Gastroenterol 14(27):4280\u20134288","journal-title":"World J Gastroenterol"},{"issue":"2","key":"756_CR4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.pharmthera.2013.04.006","volume":"139","author":"AL Alessandri","year":"2013","unstructured":"Alessandri AL, Sousa LP, Lucas CD, Rossi AG, Pinho V, Teixeira MM (2013) Resolution of inflammation: mechanisms and opportunity for drug development. Pharmacol Ther 139(2):189\u2013212","journal-title":"Pharmacol Ther"},{"issue":"7","key":"756_CR5","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1084\/jem.191.7.1197","volume":"191","author":"N Chiang","year":"2000","unstructured":"Chiang N, Fierro IM, Gronert K, Serhan CN (2000) Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J Exp Med 191(7):1197\u20131208","journal-title":"J Exp Med"},{"issue":"3","key":"756_CR6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.smim.2015.03.004","volume":"27","author":"CN Serhan","year":"2015","unstructured":"Serhan CN, Chiang N, Dalli J (2015) The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution. Semin Immunol 27(3):200\u2013215","journal-title":"Semin Immunol"},{"issue":"6837","key":"756_CR7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/35079107","volume":"411","author":"JP Hugot","year":"2001","unstructured":"Hugot JP, Chamaillard M, Zouali H, Lesage S, C\u00e9zard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn\u2019s disease. Nature 411(6837):599\u2013603","journal-title":"Nature"},{"issue":"5","key":"756_CR8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","volume":"14","author":"MF Neurath","year":"2014","unstructured":"Neurath MF (2014) Cytokines in inflammatory bowel disease. Nat Rev Immunol 14(5):329\u2013342","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"756_CR9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrgastro.2014.201","volume":"12","author":"R Atreya","year":"2015","unstructured":"Atreya R, Neurath MF (2015) IBD pathogenesis in 2014: molecular pathways controlling barrier function in IBD. Nat Rev Gastroenterol Hepatol 12(2):67\u201368","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10080","key":"756_CR10","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L (2017) Crohn\u2019s disease. Lancet 389(10080):1741\u20131755","journal-title":"Lancet"},{"issue":"3","key":"756_CR11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","volume":"10","author":"M Harbord","year":"2016","unstructured":"Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, Burisch J, de Vos M, de Vries AM, Dick AD, Juillerat P, Karlsen TH, Koutroubakis I, Lakatos PL, Orchard T, Papay P, Raine T, Reinshagen M, Thaci D, Tilg H, Carbonnel F, for the European Crohn\u2019s and Colitis Organisation [ECCO] (2016) The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 10(3):239\u2013254","journal-title":"J Crohns Colitis"},{"issue":"10114","key":"756_CR12","first-page":"2769","volume":"390","author":"SC Ng","year":"2018","unstructured":"Ng SC et al (2018) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390(10114):2769\u20132778","journal-title":"Lancet"},{"issue":"1","key":"756_CR13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomollon","year":"2017","unstructured":"Gomollon F et al (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 11(1):3\u201325","journal-title":"J Crohns Colitis"},{"key":"756_CR14","doi-asserted-by":"crossref","first-page":"175628481985686","DOI":"10.1177\/1756284819856865","volume":"12","author":"E Klenske","year":"2019","unstructured":"Klenske E et al (2019) Targeting mucosal healing in Crohn\u2019s disease: what the clinician needs to know. Ther Adv Gastroenterol 12:1756284819856865","journal-title":"Ther Adv Gastroenterol"},{"issue":"8","key":"756_CR15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A, GEMINI 2 Study Group (2013) Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 369(8):711\u2013721","journal-title":"N Engl J Med"},{"issue":"20","key":"756_CR16","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P (2016) Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med 375(20):1946\u20131960","journal-title":"N Engl J Med"},{"issue":"11","key":"756_CR17","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(18)30265-6","volume":"3","author":"R Atreya","year":"2018","unstructured":"Atreya R, Neurath MF (2018) Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol 3(11):790\u2013802","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"756_CR18","first-page":"2269","volume":"118","author":"N Kamada","year":"2008","unstructured":"Kamada N et al (2008) Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23\/IFN-gamma axis. J Clin Invest 118(6):2269\u20132280","journal-title":"J Clin Invest"},{"issue":"4","key":"756_CR19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.biocel.2008.04.027","volume":"41","author":"ZY Tan","year":"2009","unstructured":"Tan ZY, Bealgey KW, Fang Y, Gong YM, Bao S (2009) Interleukin-23: immunological roles and clinical implications. Int J Biochem Cell Biol 41(4):733\u2013735","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"756_CR20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1471-4906(00)01798-1","volume":"22","author":"MF Neurath","year":"2001","unstructured":"Neurath MF, Finotto S, Fuss I, Boirivant M, Galle PR, Strober W (2001) Regulation of T cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol 22(1):21\u201326","journal-title":"Trends Immunol"},{"issue":"5","key":"756_CR21","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/gast.2001.28702","volume":"121","author":"A Lugering","year":"2001","unstructured":"Lugering A et al (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn\u2019s disease by using a caspase-dependent pathway. Gastroenterology 121(5):1145\u20131157","journal-title":"Gastroenterology"},{"issue":"9","key":"756_CR22","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1158\/1078-0432.CCR-04-2223","volume":"11","author":"LE Broker","year":"2005","unstructured":"Broker LE, Kruyt FA, Giaccone G (2005) Cell death independent of caspases: a review. Clin Cancer Res 11(9):3155\u20133162","journal-title":"Clin Cancer Res"},{"key":"756_CR23","first-page":"218493","volume":"2014","author":"T Nunes","year":"2014","unstructured":"Nunes T, Bernardazzi C, de Souza HS (2014) Cell death and inflammatory bowel diseases: apoptosis, necrosis, and autophagy in the intestinal epithelium. Biomed Res Int 2014:218493","journal-title":"Biomed Res Int"},{"issue":"6","key":"756_CR24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1023\/A:1020546615229","volume":"19","author":"PC Rath","year":"1999","unstructured":"Rath PC, Aggarwal BB (1999) TNF-induced signaling in apoptosis. J Clin Immunol 19(6):350\u2013364","journal-title":"J Clin Immunol"},{"issue":"8","key":"756_CR25","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.3390\/ijms19082244","volume":"19","author":"Samuel O. Adegbola","year":"2018","unstructured":"Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P (2018) Anti-TNF Therapy in Crohn's Disease. Int J Mol Sci 19(8):2244.","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"756_CR26","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/gutjnl-2011-300904","volume":"61","author":"S Danese","year":"2012","unstructured":"Danese S (2012) New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 61(6):918\u2013932","journal-title":"Gut"},{"issue":"2","key":"756_CR27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology 130(2):323\u2013333 quiz 591","journal-title":"Gastroenterology"},{"issue":"1","key":"756_CR28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","volume":"13","author":"S Ben-Horin","year":"2014","unstructured":"Ben-Horin S, Kopylov U, Chowers Y (2014) Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 13(1):24\u201330","journal-title":"Autoimmun Rev"},{"issue":"9317","key":"756_CR29","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P (2002) Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet 359(9317):1541\u20131549","journal-title":"Lancet"},{"issue":"4","key":"756_CR30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrgastro.2013.253","volume":"11","author":"S Ben-Horin","year":"2014","unstructured":"Ben-Horin S, Chowers Y (2014) Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 11(4):243\u2013255","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"756_CR31","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","volume":"146","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF (2007) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146(12):829\u2013838","journal-title":"Ann Intern Med"},{"issue":"6","key":"756_CR32","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","volume":"63","author":"C Steenholdt","year":"2014","unstructured":"Steenholdt C, Brynskov J, Thomsen O\u00d8, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA (2014) Individualised therapy is more cost-effective than dose intensification in patients with Crohn\u2019s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 63(6):919\u2013927","journal-title":"Gut"},{"issue":"6","key":"756_CR33","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1053\/j.gastro.2011.08.032","volume":"141","author":"R Atreya","year":"2011","unstructured":"Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, Hildner K, Hoffman A, Kiesslich R, Rink AD, Rau TT, Rose\u2013John S, Kessler H, Schmidt J, Neurath MF (2011) Antibodies against tumor necrosis factor (TNF) induce T cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+) macrophages. Gastroenterology 141(6):2026\u20132038","journal-title":"Gastroenterology"},{"issue":"3","key":"756_CR34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.3462","volume":"20","author":"R Atreya","year":"2014","unstructured":"Atreya R, Neumann H, Neufert C, Waldner MJ, Billmeier U, Zopf Y, Willma M, App C, M\u00fcnster T, Kessler H, Maas S, Gebhardt B, Heimke-Brinck R, Reuter E, D\u00f6rje F, Rau TT, Uter W, Wang TD, Kiesslich R, Vieth M, Hannappel E, Neurath MF (2014) In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn\u2019s disease. Nat Med 20(3):313\u2013318","journal-title":"Nat Med"},{"issue":"12","key":"756_CR35","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrgastro.2013.125","volume":"10","author":"R Atreya","year":"2013","unstructured":"Atreya R, Goetz M (2013) Molecular imaging in gastroenterology. Nat Rev Gastroenterol Hepatol 10(12):704\u2013712","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"756_CR36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/gutjnl-2013-306518","volume":"64","author":"RF Leal","year":"2015","unstructured":"Leal RF, Planell N, Kajekar R, Lozano JJ, Ord\u00e1s I, Dotti I, Esteller M, Masamunt MC, Parmar H, Ricart E, Pan\u00e9s J, Salas A (2015) Identification of inflammatory mediators in patients with Crohn\u2019s disease unresponsive to anti-TNFalpha therapy. Gut 64(2):233\u2013242","journal-title":"Gut"},{"issue":"5","key":"756_CR37","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nm.4307","volume":"23","author":"NR West","year":"2017","unstructured":"West NR et al (2017) Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med 23(5):579\u2013589","journal-title":"Nat Med"},{"issue":"4","key":"756_CR38","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/gutjnl-2017-315494","volume":"68","author":"R Gaujoux","year":"2019","unstructured":"Gaujoux R, Starosvetsky E, Maimon N, Vallania F, Bar-Yoseph H, Pressman S, Weisshof R, Goren I, Rabinowitz K, Waterman M, Yanai H, Dotan I, Sabo E, Chowers Y, Khatri P, Shen-Orr SS (2019) Cell-centred meta-analysis reveals baseline predictors of anti-TNFalpha non-response in biopsy and blood of patients with IBD. Gut 68(4):604\u2013614","journal-title":"Gut"},{"issue":"5","key":"756_CR39","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.immuni.2009.05.002","volume":"30","author":"MA Curotto de Lafaille","year":"2009","unstructured":"Curotto de Lafaille MA, Lafaille JJ (2009) Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30(5):626\u2013635","journal-title":"Immunity"},{"key":"756_CR40","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fimmu.2012.00030","volume":"3","author":"S Gregori","year":"2012","unstructured":"Gregori S, Goudy KS, Roncarolo MG (2012) The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol 3:30","journal-title":"Front Immunol"},{"issue":"8","key":"756_CR41","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.4049\/jimmunol.170.8.3939","volume":"170","author":"C Mottet","year":"2003","unstructured":"Mottet C, Uhlig HH, Powrie F (2003) Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 170(8):3939\u20133943","journal-title":"J Immunol"},{"issue":"7559","key":"756_CR42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature14452","volume":"523","author":"N Gagliani","year":"2015","unstructured":"Gagliani N, Vesely MCA, Iseppon A, Brockmann L, Xu H, Palm NW, de Zoete MR, Licona-Lim\u00f3n P, Paiva RS, Ching T, Weaver C, Zi X, Pan X, Fan R, Garmire LX, Cotton MJ, Drier Y, Bernstein B, Geginat J, Stockinger B, Esplugues E, Huber S, Flavell RA (2015) Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature 523(7559):221\u2013225","journal-title":"Nature"},{"issue":"1","key":"756_CR43","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/s41467-018-05800-6","volume":"9","author":"G Schett","year":"2018","unstructured":"Schett G, Neurath MF (2018) Resolution of chronic inflammatory disease: universal and tissue-specific concepts. Nat Commun 9(1):3261","journal-title":"Nat Commun"},{"issue":"5","key":"756_CR44","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/j.gastro.2012.07.116","volume":"143","author":"P Desreumaux","year":"2012","unstructured":"Desreumaux P, Foussat A, Allez M, Beaugerie L, H\u00e9buterne X, Bouhnik Y, Nachury M, Brun V, Bastian H, Belmonte N, Ticchioni M, Duchange A, Morel\u2013Mandrino P, Neveu V, Clerget\u2013Chossat N, Forte M, Colombel J\u2013F (2012) Safety and efficacy of antigen-specific regulatory T cell therapy for patients with refractory Crohn\u2019s disease. Gastroenterology 143(5):1207\u20131217 e2","journal-title":"Gastroenterology"},{"issue":"21","key":"756_CR45","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa0907206","volume":"361","author":"EO Glocker","year":"2009","unstructured":"Glocker EO, Kotlarz D, Boztug K, Gertz EM, Sch\u00e4ffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, H\u00e4tscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C (2009) Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 361(21):2033\u20132045","journal-title":"N Engl J Med"},{"issue":"2","key":"756_CR46","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/gut.50.2.146","volume":"50","author":"H Herfarth","year":"2002","unstructured":"Herfarth H, Scholmerich J (2002) IL-10 therapy in Crohn\u2019s disease: at the crossroads. Treatment of Crohn\u2019s disease with the anti-inflammatory cytokine interleukin 10. Gut 50(2):146\u2013147","journal-title":"Gut"},{"issue":"6","key":"756_CR47","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1053\/gast.2000.20196","volume":"119","author":"S Schreiber","year":"2000","unstructured":"Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, Jacyna M, Lashner BA, Gangl A, Rutgeerts P, Isaacs K, van Deventer SJH, Koningsberger JC, Cohard M, LeBeaut A, Hanauer SB (2000) Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn\u2019s disease. Crohn\u2019s disease IL-10 cooperative study group. Gastroenterology 119(6):1461\u20131472","journal-title":"Gastroenterology"},{"issue":"9","key":"756_CR48","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/ibd.22929","volume":"18","author":"A Mizoguchi","year":"2012","unstructured":"Mizoguchi A (2012) Healing of intestinal inflammation by IL-22. Inflamm Bowel Dis 18(9):1777\u20131784","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"756_CR49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd4176","volume":"13","author":"R Sabat","year":"2014","unstructured":"Sabat R, Ouyang W, Wolk K (2014) Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 13(1):21\u201338","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"756_CR50","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.gastro.2017.03.015","volume":"153","author":"MT Chiriac","year":"2017","unstructured":"Chiriac MT, Buchen B, Wandersee A, Hundorfean G, G\u00fcnther C, Bourjau Y, Doyle SE, Frey B, Ekici AB, B\u00fcttner C, Weigmann B, Atreya R, Wirtz S, Becker C, Siebler J, Neurath MF (2017) Activation of epithelial signal transducer and activator of transcription 1 by interleukin 28 controls mucosal healing in mice with colitis and is increased in mucosa of patients with inflammatory bowel disease. Gastroenterology 153(1):123\u2013138 e8","journal-title":"Gastroenterology"},{"issue":"1","key":"756_CR51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4049\/jimmunol.1501312","volume":"196","author":"O Medina-Contreras","year":"2016","unstructured":"Medina-Contreras O, Harusato A, Nishio H, Flannigan KL, Ngo V, Leoni G, Neumann PA, Geem D, Lili LN, Ramadas RA, Chassaing B, Gewirtz AT, Kohlmeier JE, Parkos CA, Towne JE, Nusrat A, Denning TL (2016) Cutting edge: IL-36 receptor promotes resolution of intestinal damage. J Immunol 196(1):34\u201338","journal-title":"J Immunol"},{"issue":"1","key":"756_CR52","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/imr.12192","volume":"260","author":"CC Bain","year":"2014","unstructured":"Bain CC, Mowat AM (2014) Macrophages in intestinal homeostasis and inflammation. Immunol Rev 260(1):102\u2013117","journal-title":"Immunol Rev"},{"issue":"1","key":"756_CR53","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/MIB.0b013e3182a69dca","volume":"20","author":"EC Steinbach","year":"2014","unstructured":"Steinbach EC, Plevy SE (2014) The role of macrophages and dendritic cells in the initiation of inflammation in IBD. Inflamm Bowel Dis 20(1):166\u2013175","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"756_CR54","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000296507","volume":"2","author":"A Parihar","year":"2010","unstructured":"Parihar A, Eubank TD, Doseff AI (2010) Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death. J Innate Immun 2(3):204\u2013215","journal-title":"J Innate Immun"},{"issue":"6","key":"756_CR55","first-page":"1297","volume":"21","author":"D Lissner","year":"2015","unstructured":"Lissner D et al (2015) Monocyte and M1 macrophage-induced barrier defect contributes to chronic intestinal inflammation in IBD. Inflamm Bowel Dis 21(6):1297\u20131305","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"756_CR56","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3109\/08820139.2014.909456","volume":"43","author":"W Zhu","year":"2014","unstructured":"Zhu W, Yu J, Nie Y, Shi XK, Liu Y, Li F, Zhang XL (2014) Disequilibrium of M1 and M2 macrophages correlates with the development of experimental inflammatory bowel diseases. Immunol Investig 43(7):638\u2013652","journal-title":"Immunol Investig"},{"issue":"2","key":"756_CR57","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.devcel.2016.06.029","volume":"38","author":"MR Elliott","year":"2016","unstructured":"Elliott MR, Ravichandran KS (2016) The dynamics of apoptotic cell clearance. Dev Cell 38(2):147\u2013160","journal-title":"Dev Cell"},{"issue":"4","key":"756_CR58","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.4049\/jimmunol.1601520","volume":"198","author":"MR Elliott","year":"2017","unstructured":"Elliott MR, Koster KM, Murphy PS (2017) Efferocytosis signaling in the regulation of macrophage inflammatory responses. J Immunol 198(4):1387\u20131394","journal-title":"J Immunol"},{"issue":"4","key":"756_CR59","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/cells8040344","volume":"8","author":"Onali","year":"2019","unstructured":"Onali S, A Favale, and MC Fantini (2019) The Resolution of Intestinal Inflammation: The Peace-Keeper's Perspective. Cells 8(4):34","journal-title":"Cells"},{"issue":"9511","key":"756_CR60","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(06)68265-2","volume":"367","author":"DJ Marks","year":"2006","unstructured":"Marks DJ, Harbord MWN, MacAllister R, Rahman FZ, Young J, al-Lazikani B, Lees W, Novelli M, Bloom S, Segal AW (2006) Defective acute inflammation in Crohn\u2019s disease: a clinical investigation. Lancet 367(9511):668\u2013678","journal-title":"Lancet"},{"issue":"5","key":"756_CR61","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI28508","volume":"116","author":"Y Iwakura","year":"2006","unstructured":"Iwakura Y, Ishigame H (2006) The IL-23\/IL-17 axis in inflammation. J Clin Invest 116(5):1218\u20131222","journal-title":"J Clin Invest"},{"issue":"6","key":"756_CR62","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1084\/jem.20101712","volume":"208","author":"A Geremia","year":"2011","unstructured":"Geremia A, Arancibia-C\u00e1rcamo CV, Fleming MPP, Rust N, Singh B, Mortensen NJ, Travis SPL, Powrie F (2011) IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 208(6):1127\u20131133","journal-title":"J Exp Med"},{"issue":"10","key":"756_CR63","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/gut.2006.115402","volume":"56","author":"D McGovern","year":"2007","unstructured":"McGovern D, Powrie F (2007) The IL-23 axis plays a key role in the pathogenesis of IBD. Gut 56(10):1333\u20131336","journal-title":"Gut"},{"issue":"5804","key":"756_CR64","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","volume":"314","author":"RH Duerr","year":"2006","unstructured":"Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH (2006) A genome-wide association study identifies IL-23R as an inflammatory bowel disease gene. Science 314(5804):1461\u20131463","journal-title":"Science"},{"issue":"2","key":"756_CR65","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.immuni.2010.08.010","volume":"33","author":"PP Ahern","year":"2010","unstructured":"Ahern PP, Schiering C, Buonocore S, McGeachy MJ, Cua DJ, Maloy KJ, Powrie F (2010) Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 33(2):279\u2013288","journal-title":"Immunity"},{"issue":"12","key":"756_CR66","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/gut.2007.135053","volume":"57","author":"T Kobayashi","year":"2008","unstructured":"Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, Chinen H, Saito R, Kitazume MT, Nakazawa A, Sugita A, Koganei K, Isobe K, Hibi T (2008) IL-23 differentially regulates the Th1\/Th17 balance in ulcerative colitis and Crohn\u2019s disease. Gut 57(12):1682\u20131689","journal-title":"Gut"},{"issue":"10080","key":"756_CR67","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","volume":"389","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, Sandborn WJ, D'Haens G, Pan\u00e9s J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, B\u00f6cher WO (2017) Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 389(10080):1699\u20131709","journal-title":"Lancet"},{"issue":"1","key":"756_CR68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","volume":"153","author":"BE Sands","year":"2017","unstructured":"Sands BE, Chen J, Feagan BG, Penney M, Rees WA, Danese S, Higgins PDR, Newbold P, Faggioni R, Patra K, Li J, Klekotka P, Morehouse C, Pulkstenis E, Drappa J, van der Merwe R, Gasser RA Jr (2017) Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn\u2019s disease: a phase 2a study. Gastroenterology 153(1):77\u201386 e6","journal-title":"Gastroenterology"},{"issue":"5","key":"756_CR69","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","volume":"68","author":"H Schmitt","year":"2019","unstructured":"Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, Hirschmann S, Hildner K, Waldner MJ, Mudter J, Hartmann A, Gr\u00fctzmann R, Neufert C, M\u00fcnster T, Neurath MF, Atreya R (2019) Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease. Gut 68(5):814\u2013828","journal-title":"Gut"},{"issue":"7203","key":"756_CR70","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature07201","volume":"454","author":"R Medzhitov","year":"2008","unstructured":"Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454(7203):428\u2013435","journal-title":"Nature"},{"issue":"4","key":"756_CR71","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1096\/fj.201601222R","volume":"31","author":"CN Serhan","year":"2017","unstructured":"Serhan CN (2017) Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. FASEB J 31(4):1273\u20131288","journal-title":"FASEB J"},{"issue":"8","key":"756_CR72","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd.2016.39","volume":"15","author":"JN Fullerton","year":"2016","unstructured":"Fullerton JN, Gilroy DW (2016) Resolution of inflammation: a new therapeutic frontier. Nat Rev Drug Discov 15(8):551\u2013567","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"756_CR73","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.smim.2015.03.014","volume":"27","author":"SE Headland","year":"2015","unstructured":"Headland SE, Norling LV (2015) The resolution of inflammation: principles and challenges. Semin Immunol 27(3):149\u2013160","journal-title":"Semin Immunol"},{"issue":"3","key":"756_CR74","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.smim.2015.05.003","volume":"27","author":"D Gilroy","year":"2015","unstructured":"Gilroy D, De Maeyer R (2015) New insights into the resolution of inflammation. Semin Immunol 27(3):161\u2013168","journal-title":"Semin Immunol"},{"issue":"3","key":"756_CR75","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.immuni.2014.02.009","volume":"40","author":"CD Buckley","year":"2014","unstructured":"Buckley CD, Gilroy DW, Serhan CN (2014) Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40(3):315\u2013327","journal-title":"Immunity"},{"issue":"5","key":"756_CR76","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.immuni.2012.03.010","volume":"36","author":"S Uderhardt","year":"2012","unstructured":"Uderhardt S, Herrmann M, Oskolkova OV, Aschermann S, Bicker W, Ipseiz N, Sarter K, Frey B, Rothe T, Voll R, Nimmerjahn F, Bochkov VN, Schett G, Kr\u00f6nke G (2012) 12\/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity 36(5):834\u2013846","journal-title":"Immunity"},{"issue":"7","key":"756_CR77","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1084\/jem.20161070","volume":"214","author":"S Uderhardt","year":"2017","unstructured":"Uderhardt S, Ackermann JA, Fillep T, Hammond VJ, Willeit J, Santer P, Mayr M, Biburger M, Miller M, Zellner KR, Stark K, Zarbock A, Rossaint J, Schubert I, Mielenz D, Dietel B, Raaz-Schrauder D, Ay C, Gremmel T, Thaler J, Heim C, Herrmann M, Collins PW, Schabbauer G, Mackman N, Voehringer D, Nadler JL, Lee JJ, Massberg S, Rauh M, Kiechl S, Schett G, O\u2019Donnell VB, Kr\u00f6nke G (2017) Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease. J Exp Med 214(7):2121\u20132138","journal-title":"J Exp Med"},{"issue":"10","key":"756_CR78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076532","volume":"8","author":"M Masoodi","year":"2013","unstructured":"Masoodi M, Pearl DS, Eiden M, Shute JK, Brown JF, Calder PC, Trebble TM (2013) Altered colonic mucosal polyunsaturated fatty acid (PUFA) derived lipid mediators in ulcerative colitis: new insight into relationship with disease activity and pathophysiology. PLoS One 8(10):e76532","journal-title":"PLoS One"},{"issue":"1","key":"756_CR79","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.crohns.2013.03.013","volume":"8","author":"DS Pearl","year":"2014","unstructured":"Pearl DS, Masoodi M, Eiden M, Br\u00fcmmer J, Gullick D, Mckeever TM, Whittaker MA, Nitch-Smith H, Brown JF, Shute JK, Mills G, Calder PC, Trebble TM (2014) Altered colonic mucosal availability of n-3 and n-6 polyunsaturated fatty acids in ulcerative colitis and the relationship to disease activity. J Crohns Colitis 8(1):70\u201379","journal-title":"J Crohns Colitis"},{"issue":"7","key":"756_CR80","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(17)30031-6","volume":"2","author":"G Rogler","year":"2017","unstructured":"Rogler G (2017) Resolution of inflammation in inflammatory bowel disease. Lancet Gastroenterol Hepatol 2(7):521\u2013530","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"756_CR81","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/1756283X16644242","volume":"9","author":"SM Vindigni","year":"2016","unstructured":"Vindigni SM, Zisman TL, Suskind DL, Damman CJ (2016) The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Ther Adv Gastroenterol 9(4):606\u2013625","journal-title":"Ther Adv Gastroenterol"},{"issue":"7","key":"756_CR82","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00335-009-9204-7","volume":"20","author":"IM Carroll","year":"2009","unstructured":"Carroll IM, Threadgill DW, Threadgill DS (2009) The gastrointestinal microbiome: a malleable, third genome of mammals. Mamm Genome 20(7):395\u2013403","journal-title":"Mamm Genome"},{"issue":"4","key":"756_CR83","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrmicro2540","volume":"9","author":"A Spor","year":"2011","unstructured":"Spor A, Koren O, Ley R (2011) Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 9(4):279\u2013290","journal-title":"Nat Rev Microbiol"},{"key":"756_CR84","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JIR.S116088","volume":"10","author":"ER Lane","year":"2017","unstructured":"Lane ER, Zisman TL, Suskind DL (2017) The microbiota in inflammatory bowel disease: current and therapeutic insights. J Inflamm Res 10:63\u201373","journal-title":"J Inflamm Res"},{"key":"756_CR85","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.3389\/fmicb.2018.02247","volume":"9","author":"T Zuo","year":"2018","unstructured":"Zuo T, Ng SC (2018) The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Front Microbiol 9:2247","journal-title":"Front Microbiol"},{"issue":"1","key":"756_CR86","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41598-018-37143-z","volume":"9","author":"Y Sun","year":"2019","unstructured":"Sun Y, Li L, Xia Y, Li W, Wang K, Wang L, Miao Y, Ma S (2019) The gut microbiota heterogeneity and assembly changes associated with the IBD. Sci Rep 9(1):440","journal-title":"Sci Rep"},{"issue":"2","key":"756_CR87","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/gut.2005.073817","volume":"55","author":"C Manichanh","year":"2006","unstructured":"Manichanh C et al (2006) Reduced diversity of faecal microbiota in Crohn\u2019s disease revealed by a metagenomic approach. Gut 55(2):205\u2013211","journal-title":"Gut"},{"issue":"6","key":"756_CR88","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ibd.20101","volume":"13","author":"S Sepehri","year":"2007","unstructured":"Sepehri S, Kotlowski R, Bernstein CN, Krause DO (2007) Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis 13(6):675\u2013683","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"756_CR89","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.chom.2014.02.005","volume":"15","author":"D Gevers","year":"2014","unstructured":"Gevers D, Kugathasan S, Denson LA, V\u00e1zquez-Baeza Y, van Treuren W, Ren B, Schwager E, Knights D, Song SJ, Yassour M, Morgan XC, Kostic AD, Luo C, Gonz\u00e1lez A, McDonald D, Haberman Y, Walters T, Baker S, Rosh J, Stephens M, Heyman M, Markowitz J, Baldassano R, Griffiths A, Sylvester F, Mack D, Kim S, Crandall W, Hyams J, Huttenhower C, Knight R, Xavier RJ (2014) The treatment-naive microbiome in new-onset Crohn\u2019s disease. Cell Host Microbe 15(3):382\u2013392","journal-title":"Cell Host Microbe"},{"issue":"2","key":"756_CR90","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1053\/j.gastro.2016.10.012","volume":"152","author":"RB Sartor","year":"2017","unstructured":"Sartor RB, Wu GD (2017) Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology 152(2):327\u2013339 e4","journal-title":"Gastroenterology"},{"issue":"8","key":"756_CR91","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/ajg.2010.84","volume":"105","author":"T Ohkusa","year":"2010","unstructured":"Ohkusa T, Kato K, Terao S, Chiba T, Mabe K, Murakami K, Mizokami Y, Sugiyama T, Yanaka A, Takeuchi Y, Yamato S, Yokoyama T, Okayasu I, Watanabe S, Tajiri H, Sato N, Japan UC Antibiotic Therapy Study Group (2010) Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol 105(8):1820\u20131829","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"756_CR92","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.crohns.2014.05.010","volume":"8","author":"D Turner","year":"2014","unstructured":"Turner D, Levine A, Kolho KL, Shaoul R, Ledder O (2014) Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report. J Crohns Colitis 8(11):1464\u20131470","journal-title":"J Crohns Colitis"},{"issue":"8","key":"756_CR93","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1172\/JCI75436","volume":"124","author":"Y Haberman","year":"2014","unstructured":"Haberman Y, Tickle TL, Dexheimer PJ, Kim MO, Tang D, Karns R, Baldassano RN, Noe JD, Rosh J, Markowitz J, Heyman MB, Griffiths AM, Crandall WV, Mack DR, Baker SS, Huttenhower C, Keljo DJ, Hyams JS, Kugathasan S, Walters TD, Aronow B, Xavier RJ, Gevers D, Denson LA (2014) Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest 124(8):3617\u20133633","journal-title":"J Clin Invest"},{"issue":"6","key":"756_CR94","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/gutjnl-2015-310746","volume":"66","author":"H Sokol","year":"2017","unstructured":"Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I, Cosnes J, Seksik P, Langella P, Skurnik D, Richard ML, Beaugerie L (2017) Fungal microbiota dysbiosis in IBD. Gut 66(6):1039\u20131048","journal-title":"Gut"},{"issue":"1","key":"756_CR95","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13073-016-0331-y","volume":"8","author":"KA Shaw","year":"2016","unstructured":"Shaw KA, Bertha M, Hofmekler T, Chopra P, Vatanen T, Srivatsa A, Prince J, Kumar A, Sauer C, Zwick ME, Satten GA, Kostic AD, Mulle JG, Xavier RJ, Kugathasan S (2016) Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease. Genome Med 8(1):75","journal-title":"Genome Med"},{"issue":"6","key":"756_CR96","first-page":"978","volume":"20","author":"S Rajca","year":"2014","unstructured":"Rajca S et al (2014) Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn\u2019s disease. Inflamm Bowel Dis 20(6):978\u2013986","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"756_CR97","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3748\/wjg.v20.i5.1165","volume":"20","author":"L Antoni","year":"2014","unstructured":"Antoni L et al (2014) Intestinal barrier in inflammatory bowel disease. World J Gastroenterol 20(5):1165\u20131179","journal-title":"World J Gastroenterol"},{"issue":"1","key":"756_CR98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00423-012-1030-9","volume":"398","author":"S Jager","year":"2013","unstructured":"Jager S, Stange EF, Wehkamp J (2013) Inflammatory bowel disease: an impaired barrier disease. Langenbeck's Arch Surg 398(1):1\u201312","journal-title":"Langenbeck's Arch Surg"},{"issue":"1","key":"756_CR99","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","volume":"13","author":"HS de Souza","year":"2016","unstructured":"de Souza HS, Fiocchi C (2016) Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol 13(1):13\u201327","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"756_CR100","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/gutjnl-2015-309698","volume":"64","author":"T Billiet","year":"2015","unstructured":"Billiet T, Vande Casteele N, van Stappen T, Princen F, Singh S, Gils A, Ferrante M, van Assche G, Cleynen I, Vermeire S (2015) Immunogenicity to infliximab is associated with HLA-DRB1. Gut 64(8):1344\u20131345","journal-title":"Gut"},{"issue":"8","key":"756_CR101","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/gut.2008.163667","volume":"58","author":"S Brand","year":"2009","unstructured":"Brand S (2009) Crohn\u2019s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn\u2019s disease. Gut 58(8):1152\u20131167","journal-title":"Gut"},{"issue":"11","key":"756_CR102","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/ng.221","volume":"40","author":"A Franke","year":"2008","unstructured":"Franke A et al (2008) Sequence variants in IL-10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 40(11):1319\u20131323","journal-title":"Nat Genet"},{"issue":"4","key":"756_CR103","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ng.553","volume":"42","author":"A Franke","year":"2010","unstructured":"Franke A et al (2010) Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL). Nat Genet 42(4):292\u2013294","journal-title":"Nat Genet"},{"issue":"6837","key":"756_CR104","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/35079114","volume":"411","author":"Y Ogura","year":"2001","unstructured":"Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nu\u00f1ez G, Cho JH (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn\u2019s disease. Nature 411(6837):603\u2013606","journal-title":"Nature"},{"issue":"2","key":"756_CR105","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/ng1954","volume":"39","author":"J Hampe","year":"2007","unstructured":"Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, Albrecht M, Mayr G, de la Vega FM, Briggs J, G\u00fcnther S, Prescott NJ, Onnie CM, H\u00e4sler R, Sipos B, F\u00f6lsch UR, Lengauer T, Platzer M, Mathew CG, Krawczak M, Schreiber S (2007) A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 39(2):207\u2013211","journal-title":"Nat Genet"},{"issue":"1","key":"756_CR106","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nm.2069","volume":"16","author":"R Cooney","year":"2010","unstructured":"Cooney R, Baker J, Brain O, Danis B, Pichulik T, Allan P, Ferguson DJP, Campbell BJ, Jewell D, Simmons A (2010) NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 16(1):90\u201397","journal-title":"Nat Med"},{"issue":"1","key":"756_CR107","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ni.1823","volume":"11","author":"LH Travassos","year":"2010","unstructured":"Travassos LH, Carneiro LAM, Ramjeet M, Hussey S, Kim YG, Magalh\u00e3es JG, Yuan L, Soares F, Chea E, le Bourhis L, Boneca IG, Allaoui A, Jones NL, Nu\u00f1ez G, Girardin SE, Philpott DJ (2010) Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 11(1):55\u201362","journal-title":"Nat Immunol"},{"issue":"12","key":"756_CR108","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/gut.2009.199679","volume":"60","author":"CW Lees","year":"2011","unstructured":"Lees CW, Barrett JC, Parkes M, Satsangi J (2011) New IBD genetics: common pathways with other diseases. Gut 60(12):1739\u20131753","journal-title":"Gut"},{"issue":"6","key":"756_CR109","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/MEG.0b013e3282f495dd","volume":"20","author":"S Hafner","year":"2008","unstructured":"Hafner S, Timmer A, Herfarth H, Rogler G, Sch\u00f6lmerich J, Sch\u00e4ffler A, Ehrenstein B, Jilg W, Ott C, Strauch UG, Obermeier F (2008) The role of domestic hygiene in inflammatory bowel diseases: hepatitis A and worm infestations. Eur J Gastroenterol Hepatol 20(6):561\u2013566","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"756_CR110","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1136\/gutjnl-2015-310297","volume":"66","author":"PA Ruiz","year":"2017","unstructured":"Ruiz PA, Mor\u00f3n B, Becker HM, Lang S, Atrott K, Spalinger MR, Scharl M, Wojtal KA, Fischbeck-Terhalle A, Frey-Wagner I, Hausmann M, Kraemer T, Rogler G (2017) Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome. Gut 66(7):1216\u20131224","journal-title":"Gut"},{"issue":"3","key":"756_CR111","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/mi.2013.78","volume":"7","author":"G Pineton de Chambrun","year":"2014","unstructured":"Pineton de Chambrun G et al (2014) Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice. Mucosal Immunol 7(3):589\u2013601","journal-title":"Mucosal Immunol"},{"issue":"7541","key":"756_CR112","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature14232","volume":"519","author":"B Chassaing","year":"2015","unstructured":"Chassaing B, Koren O, Goodrich JK, Poole AC, Srinivasan S, Ley RE, Gewirtz AT (2015) Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 519(7541):92\u201396","journal-title":"Nature"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-019-00756-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00281-019-00756-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-019-00756-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T23:05:33Z","timestamp":1600815933000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00281-019-00756-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,24]]},"references-count":112,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["756"],"URL":"https:\/\/doi.org\/10.1007\/s00281-019-00756-1","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,24]]},"assertion":[{"value":"12 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}